Workflow
佐力药业(300181):公司信息更新报告:2025H1利润快速增长,战略性拓展布局大健康

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 1.599 billion yuan in H1 2025, representing a year-on-year increase of 11.99%. The net profit attributable to shareholders was 374 million yuan, up 26.16% year-on-year. The net profit excluding non-recurring items was 372 million yuan, an increase of 27.24% year-on-year [4][5] - The company maintains a positive outlook on the growth potential of its Wuling and Bailing product series and has kept its profit forecasts for 2025-2027 unchanged, expecting net profits of 667 million yuan, 845 million yuan, and 1.067 billion yuan respectively for those years [4][5] Financial Performance Summary - In H1 2025, the company's gross margin was 63.01%, an increase of 0.39 percentage points, and the net profit margin was 23.71%, up 2.71 percentage points. The sales expense ratio decreased by 2.95 percentage points to 31.23%, while the management expense ratio fell by 0.71 percentage points to 3.03% [4] - The revenue from the Wuling series was 897 million yuan, a growth of 7.23%, with a gross margin of 86.66%. The Bailing series saw revenue of 113 million yuan, up 38.51%, with a gross margin of 63.95% [5] - The company has established a joint research and development center with Zhejiang University to leverage AI technology for the development of innovative health products, which is expected to enhance future performance [6] Financial Projections - The company forecasts revenues of 3.246 billion yuan, 3.814 billion yuan, and 4.472 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 25.9%, 17.5%, and 17.3% [7][9] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.95 yuan, 1.20 yuan, and 1.52 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 21.3, 16.8, and 13.3 [7][9]